The South Korean Ministry of Food and Drug Safety (MFDS) has recently cleared Pluristem’s upgraded manufacturing process in its new facility in Haifa, Israel. The cells produced at
Nintedanib is the first targeted treatment for IPF to consistently meet the primary endpoint in two international Phase III trials with identical design. In the two 52 week
The product has the potential to be the first of its kind to treat overdose from opioid prescription painkillers and heroin – a growing epidemic in the US.
The Breakthrough Therapy designation was granted based on interim efficacy and safety results from an ongoing Phase I/II study of CO-1686. CO-1686 is the company’s novel, oral, targeted
In addition, Endo will assume an existing third party royalty obligation on net sales. The transaction will be financed with Endo’s current cash on hand. Sumavel DosePro is
Fabrus has been successful in generating antibodies against very difficult, therapeutically important cell surface receptors and ion channels resulting in an internal pipeline that includes next generation antibodies
GELESIS100 is a smart pill that is designed to treat the physiological symptoms of hunger without surgery, invasive procedures or systemic absorption. To date, Gelesis100 has generated compelling
Their findings have been published in the February issue of Hepatology, 2014. This medical discovery has opened up a brand new chapter in explaining the mechanism of Hepatitis
Pirfenidone is an investigational therapy in the US and has not been approved by the US Food and Drug Administration (FDA). Expanded access programs provide a mechanism for
The distribution center represents a significant capacity upgrade in DKSH’s healthcare infrastructure in Malaysia. The new facility in Hicom Industrial Estate, Shah Alam replaces DKSH Malaysia’s older Central
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.